Page 1143 - Williams Hematology ( PDFDrive )

1118 Part VIII: Monocytes and Macrophages Chapter 71: Inflammatory and Malignant Histiocytosis 1119

115. Diette GB, Scatarige JC, Haponik EF, et al: Do high-resolution CT findings of usual 149. Gazziola C, Cordani N, Wasserman B, et al: Malignant fibrous histiocytoma: A pro-
interstitial pneumonitis obviate lung biopsy? Views of pulmonologists. Respiration posed cellular origin and identification of its characterizing gene transcripts. Int J Oncol
72:134–141, 2005. 23:343–351, 2003.
116. Soler P, Bergeron A, Kambouchner M, et al: Is high-resolution computed tomography 150. Lee Y, John M, Edwards S: Molecular classification of synovial sarcomas, leiomyosar-
a reliable tool to predict the histopathological activity of pulmonary Langerhans cell comas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer
histiocytosis? Am J Respir Crit Care Med 162:264–270, 2000. 88:510–515, 2003.
117. Pardanani A, Phyliky RL, Li CY, Tefferi A: 2-Chlorodeoxyadenosine therapy for dis- 151. Nakayama R, Nemoto T, Takahashi H, et al: Gene expression analysis of soft tissue
seminated Langerhans cell histiocytosis. Mayo Clin Proc 78:301–306, 2003. sarcomas: Characterization and reclassification of malignant fibrous histiocytoma. Mod
118. Saven A, Foon KA, Piro LD: 2-Chlorodeoxyadenosine-induced complete remissions in Pathol 20:749–759, 2007.
Langerhans-cell histiocytosis. Ann Intern Med 121:430–432, 1994. 152. Bramwell VH, Steward WP, Nooij M, et al: Neoadjuvant chemotherapy with doxoru-
119. Cantu MA, Lupo PJ, Bilgi M, et al: Optimal therapy for adults with Langerhans cell bicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosar-
histiocytosis bone lesions. PLoS One 7:e43257, 2012. coma Intergroup study. J Clin Oncol 17:3260–3269, 1999.
120. Brown RE: Bisphosphonates as antialveolar macrophage therapy in pulmonary Langer- 153. Daw NC, Billups CA, Pappo AS, et al: Malignant fibrous histiocytoma and other fibro-
hans cell histiocytosis? Med Pediatr Oncol 36:641–643, 2001. histiocytic tumors in pediatric patients: The St. Jude Children’s Research Hospital expe-
121. Farran RP, Zaretski E, Egeler RM: Treatment of Langerhans cell histiocytosis with rience. Cancer 97:2839–2847, 2003.
pamidronate. J Pediatr Hematol Oncol 23:54–56, 2001. 154. Picci P, Bacci G, Ferrari S, Mercuri M: Neoadjuvant chemotherapy in malignant fibrous
122. Girschikofsky M, Arico M, Castillo D, et al: Management of adult patients with Langer- histiocytoma of bone and in osteosarcoma located in the extremities: Analogies and
hans cell histiocytosis: Recommendations from an expert panel on behalf of Euro-His- differences between the two tumors. Ann Oncol 8:1107–1115, 1997.
tio-Net. Orphanet J Rare Dis 8:72, 2013. 155. Jaffe HS: Metabolic, Degenerative, and Inflammatory Diseases of Bones and Joints. Lea
123. Arceci RJ, Allen CE, Dunkel I, et al: Evaluation of afuresertib, an oral pan-AKT inhibi- and Febiger, Philadelphia, 1972.
tor, in patients with Langerhans cell histiocytosis. 55th Blood 122(21):2907, 2013. 156. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al: Erdheim-Chester disease.
124. Mogulkoc N, Veral A, Bishop PW, et al: Pulmonary Langerhans’ cell histiocytosis: Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 75:157–169,
Radiologic resolution following smoking cessation. Chest 115:1452–1455, 1999. 1996.
125. Shah RJ, Kotloff RM: Lung transplantation for obstructive lung diseases. Semin Respir 157. Al-Quran S, Reith J, Bradley J, Rimsza L: Erdheim-Chester disease: Case report, PCR-
Crit Care Med 34:288–296, 2013. based analysis of clonality, and review of literature. Mod Pathol 15:666–672, 2002.
126. Robb-Smith AHT. Before our time: Half a century of histiocytic medullary reticulosis: 158. Chetritt J, Paradis V, Dargere D, et al: Chester-Erdheim disease: A neoplastic disorder.
A T-cell teaser? Histopathology 1990279. Hum Pathol 30:1093–1096, 1999.
127. Rappaport H: Tumors of the hematopoietic system. Atlas of Tumor Pathology, Section 159. Loddenkemper K, Hoyer B, Loddenkemper C, et al: A case of Erdheim-Chester disease
III, Fascicle 8, 49–63. Washington DC: Armed Forces Institute of Pathology. 1966. initially mistaken for Ormond’s disease. Nat Clin Pract Rheumatol 4:50–55, 2008.
128. Fonseca R, Tefferi A, Strickler JG: Follicular dendritic cell sarcoma mimicking diffuse 160. Taguchi T, Iwasaki Y, Asaba K, et al: Erdheim-Chester disease: Report of a case with
large cell lymphoma: A case report. Am J Hematol 55:148–155, 1997. PCR-based analysis of the expression of osteopontin and survivin in Xanthogranulo-
129. Wilson MS, Weiss LM, Gatter KC, et al: Malignant histiocytosis. A reassessment of mas following glucocorticoid treatment. Endocr J 55:217–223, 2008.
cases previously reported in 1975 based on paraffin section immunophenotyping stud- 161. Stoppacciaro A, Ferrarini M, Salmaggi C, et al: Immunohistochemical evidence of
ies. Cancer 66:530–536, 1990. a cytokine and chemokine network in three patients with Erdheim-Chester disease:
130. Takahashi E, Nakamura S: Histiocytic sarcoma: An updated literature review based on Implications for pathogenesis. Arthritis Rheum 54:4018–4022, 2006.
the 2008 WHO classification. J Clin Exp Hematop 53:1–8, 2013. 162. Haroche J, Charlotte F, Arnaud L, et al: High prevalence of BRAF V600E mutations
131. West DS, Dogan A, Quint PS, et al: Clonally related follicular lymphomas and Langer- in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood
hans cell neoplasms: Expanding the spectrum of transdifferentiation. Am J Surg Pathol 120:2700–2703, 2012.
37:978–986, 2013. 163. Diamond EL, Abdel-Wahab O, Pentsova E, et al: Detection of an NRAS mutation in
132. Chen W, Jaffe R, Zhang L, et al: Langerhans cell sarcoma arising from chronic lym- Erdheim-Chester disease. Blood 122:1089–1091, 2013.
phocytic lymphoma/small lymphocytic leukemia: Lineage analysis and BRAF V600E 164. Hervier B, Haroche J, Arnaud L, et al: Association of both Langerhans cell histiocytosis
mutation study. N Am J Med Sci 5:386–391, 2013. and Erdheim-Chester disease linked to the BRAFV600E mutation: A multicenter study
133. Pileri SA, Grogan TM, Harris NL, et al: Tumours of histiocytes and accessory dendritic of 23 cases. Blood 124:1119–1126, 2014.
cells: An immunohistochemical approach to classification from the International Lym- 165. Diamond EL, Dagna L, Hyman DM, et al: Consensus guidelines for the diagnosis and
phoma Study Group based on 61 cases. Histopathology 41:1–29, 2002. clinical management of Erdheim-Chester disease. Blood 124:483–492, 2014.
134. Go H, Jeon YK, Huh J, et al: Frequent detection of BRAF mutations in histiocytic and 166. Arnaud L, Hervier B, Neel A, et al: CNS involvement and treatment with interferon-al-
dendritic cell neoplasms. Histopathology 65:261–272, 2014. pha are independent prognostic factors in Erdheim-Chester disease: A multicenter sur-
135. Lauritzen AF, Delsol G, Hansen NE, et al: Histiocytic sarcomas and monoblastic leuke- vival analysis of 53 patients. Blood 117:2778–2782, 2011.
mias. A clinical, histologic, and immunophenotypical study. Am J Clin Pathol 102:45– 167. Caparros-Lefebvre D, Pruvo JP, Remy M, et al: Neuroradiologic aspects of Chester-Erd-
54, 1994. heim disease. AJNR Am J Neuroradiol 16:735–740, 1995.
136. Kamel OW, Gocke CD, Kell DL, et al: True histiocytic lymphoma: A study of 12 cases 168. Dion E, Graef C, Haroche J, et al: Imaging of thoracoabdominal involvement in Erd-
based on current definition. Leuk Lymphoma 18:81–86, 1995. heim-Chester disease. AJR Am J Roentgenol 183:1253–1260, 2004.
137. Julg BD, Weidner S, Mayr D: Pulmonary manifestation of a Langerhans cell sarcoma: 169. Gupta A, Kelly B, McGuigan JE: Erdheim-Chester disease with prominent pericardial
Case report and review of the literature. Virchows Arch 448:369–374, 2006. involvement: Clinical, radiologic, and histologic findings. Am J Med Sci 324:96–100,
138. Newman B, Hu W, Nigro K, Gilliam AC: Aggressive histiocytic disorders that can 2002.
involve the skin. J Am Acad Dermatol 56:302–316, 2007. 170. Lachenal F, Cotton F, smurs-Clavel H, et al: Neurological manifestations and neurora-
139. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: Clinicopathologic diological presentation of Erdheim-Chester disease: Report of 6 cases and systematic
analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 28:1133–1144, review of the literature. J Neurol 253:1267–1277, 2006.
2004. 171. Drier A, Haroche J, Savatovsky J, et al: Cerebral, facial, and orbital involvement in Erd-
140. Pillay K, Solomon R, Daubenton JD, Sinclair-Smith CC. Interdigitating dendritic cell heim-Chester disease: CT and MR imaging findings. Radiology 255:586–594, 2010.
sarcoma: A report of four paediatric cases and review of the literature. Histopathology 172. Caputo R, Marzano AV, Passoni E, Berti E: Unusual variants of non-Langerhans cell
44:283–291, 2004. histiocytoses. J Am Acad Dermatol 57:1031–1045, 2007.
141. Kairouz S, Hashash J, Kabbara W, et al: Dendritic cell neoplasms: An overview. Am J 173. Diamond EL, Dagna L, Hyman DM, et al: Consensus guidelines for the diagnosis and
Hematol 82:924–928, 2007. clinical management of Erdheim-Chester disease. Blood 124:483–492, 2014.
142. Porter DW, Gupte GL, Brown RM, et al: Histiocytic sarcoma with interdigitating den- 174. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R: Successful treatment of Erdheim-Chester
dritic cell differentiation. J Pediatr Hematol Oncol 26:827–830, 2004. disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 106:2992–
143. Soriano AO, Thompson MA, Admirand JH, et al: Follicular dendritic cell sarcoma: A 2994, 2005.
report of 14 cases and a review of the literature. Am J Hematol 82:725–728, 2007. 175. Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R: Interferon therapy for orbital
144. Feldman AL, Arber DA, Pittaluga S, et al: Clonally related follicular lymphomas and infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol 132:945–947,
histiocytic/dendritic cell sarcomas: Evidence for transdifferentiation of the follicular 2001.
lymphoma clone. Blood 111:5433–5439, 2008. 176. Haroche J, Amoura Z, Trad SG, et al: Variability in the efficacy of interferon-alpha in
145. Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E: Thalidomide for the treatment of Erdheim-Chester disease by patient and site of involvement: Results in eight patients.
histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol 82:932–933, Arthritis Rheum 54:3330–3336, 2006.
2007. 177. Hervier B, Arnaud L, Charlotte F, et al: Treatment of Erdheim-Chester disease with
146. Bailey KM, Castle VP, Hummel JM, et al: Thalidomide therapy for aggressive histiocytic long-term high-dose interferon-alpha. Semin Arthritis Rheum 41:907–913, 2012.
lesions in the pediatric population. J Pediatr Hematol Oncol 34:480–483, 2012. 178. Suzuki HI, Hosoya N, Miyagawa K, et al: Erdheim-Chester disease: Multisystem
147. Shukla N, Kobos R, Renaud T, et al: Successful treatment of refractory metastatic histi- involvement and management with interferon-alpha. Leuk Res 34:e21–e24, 2010.
ocytic sarcoma with alemtuzumab. Cancer 118:3719–3724, 2012. 179. Haroche J, Amoura Z, Charlotte F, et al: Imatinib mesylate for platelet-derived growth
148. Uchida K, Kobayashi S, Inukai T, et al: Langerhans cell sarcoma emanating from the factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 111:5413–5415,
upper arm skin: Successful treatment by MAID regimen. J Orthop Sci 13:89–93, 2008. 2008.

Kaushansky_chapter 71_p1101-1120.indd 1118 9/17/15 3:51 PM